| Study | Level of study | Group | Sex (M/F) | Age, mean ± SD (y) | Pain duration, mean ± SD | Herpes involved area | Intervention (V) | Last follow-uptime (m) | Outcome |
| Cheng-Fu Wan, 2021 | RCT | S-PRF | 23/35 | 69.96 ± 13.66 d | 65.14 ± 18.53 d | Trigeminal | 40 | 6 | VAS, SF-36 score, mean dose of pregabalin, adverse events | H-PRF | 21/36 | 70.54 ± 14.02 | 67.28 ± 19.64 d | 60 V to 100 |
| Hongxi Li, 2021 | RCT | S-PRF | 10/16 | 64.15 ± 12.29 | 56.69 ± 13.70 d | Trigeminal | 45 | 6 | VAS, SF-36, treatment efficiency, adverse events | H-PRF | 12/14 | 66.62 ± 8.21 | 58.85 ± 16.62 d | 65 |
| Tao Song, 2019 | RCT | Sham group | 20/27 | 65.96 ± 13.66 | 63.14 ± 18.53 d | Trigeminal | | 6 | VAS, SF-36, dosage of pregabalin, adverse events | H-PRF | 21/25 | 65.54 ± 13.28 | 59.28 ± 16.64 d | 60 to 90 |
| Bo Wang, 2020 | RCT | S-PRF | 13/19 | 71.42 ± 5.43 | 22.40 ± 5.46 d | Thoracolumbar | 47.73 ± 2.45 | 3 | NRS, SQS, gabapentin and tramadol doses, clinically meaningful PHN cases | H-PRF | 15/17 | 72.81 ± 5.92 | 23.20 ± 4.61 d | 76.50 ± 5.61 |
| Zhenkai Han, 2020 | RCT | S-PRF | 17/19 | 67.67 ± 6.77 | 3.08 ± 1.07 m | Thoracolumbar | 45 | 12 | VAS, SF-36, patient satisfaction, adverse events | H-PRF | 16/20 | 68.19 ± 10.42 | 3.38 ± 0.93 m | 65 |
| Shenshen Lin, 2021 | RCT | Sham group | 16/14 | 67.6 ± 10.6 | 16.0 ± 8.7 d | Neck, upper limbs, etc | | 3 | VAS, PSQI, SF-36, use of tramadol and gabapentin, adverse events | H-PRF | 18/12 | 66.8 ± 8.4 | 15.2 ± 7.3 d | 90 V–100 |
|
|